EUVIMEDEUVIMED entdecken
Crossref

Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG

Iris Amitay-Laish iD, Keila Mitsunaga iD, Pablo L Ortiz-Romero iD, Adèle de Masson iD, Erika Morsia iD, Jose A Sanches iD, Paula A Enz iD, Vasiliki Nikolaou iD, Constanze Jonak iD, Stefanie Porkert iD, Yael A Leshem iD, Emily Avitan-Hersh iD und 1 weitere

British Journal of Dermatology · 19.05.2026 · 194 (6) · 1178-1180

DOI: 10.1093/bjd/ljag089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 09.03.2026. Verfasst von Iris Amitay-Laish und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Janus kinase inhibitors (JAKis) are increasingly used in patients with mycosis fungoides (MF)/Sézary syndrome (SS), often outside of intentional lymphoma-directed treatment, yet their real-world impact remains uncertain and poorly characterized. Our multicentre experience suggests that disease acceleration may occur in specific clinical contexts, particularly in patients initially diagnosed with dermatitis who were later recognized as having MF/SS while receiving JAKis. It remains uncertain whether this acceleration represents a direct drug-related effect. Observations in post-transplant settings warrant further investigation, particularly given ruxolitinib’s role in this context. However, symptom-focused benefit may be observed in carefully selected patients. Collectively, these findings highlight that the use of JAKis in treating patients with MF/SS should be undertaken with caution.

Autor:innen und Institutionen

  • Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Iris Amitay-Laish, Keila Mitsunaga, Pablo L Ortiz-Romero, Adèle de Masson, Erika Morsia, Jose A Sanches, Paula A Enz, Vasiliki Nikolaou, Constanze Jonak, Stefanie Porkert, Yael A Leshem, Emily Avitan-Hersh, Emmilia Hodak

Zitieren

APA

Amitay-Laish, I., Mitsunaga, K., Ortiz-Romero, P. L., de Masson, A., Morsia, E., Sanches, J. A., Enz, P. A., Nikolaou, V., Jonak, C., Porkert, S., Leshem, Y. A., Avitan-Hersh, E., & Hodak, E. (2026). Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG. British Journal of Dermatology, 194(6), 1178-1180. https://doi.org/10.1093/bjd/ljag089

Vancouver

Amitay-Laish I, Mitsunaga K, Ortiz-Romero PL, de Masson A, Morsia E, Sanches JA, et al. Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG. British Journal of Dermatology. 2026;194(6):1178-1180. doi:10.1093/bjd/ljag089

BibTeX
@article{AmitayLaish2026,
  author = {Amitay-Laish, Iris and Mitsunaga, Keila and Ortiz-Romero, Pablo L and de Masson, Adèle and Morsia, Erika and Sanches, Jose A and Enz, Paula A and Nikolaou, Vasiliki and Jonak, Constanze and Porkert, Stefanie and Leshem, Yael A and Avitan-Hersh, Emily and Hodak, Emmilia},
  title = {Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {194},
  number = {6},
  pages = {1178--1180},
  doi = {10.1093/bjd/ljag089}
}
Kostenlos starten →